Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun;22(6):765-766.
doi: 10.1016/S1473-3099(22)00283-3.

Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?

Rob W van der Pluijm  1 , Thomas J Peto  1 , Mainga Hamaluba  2 , James J Callery  1 , Rupam Tripura  1 , Nicholas J White  1 , Arjen M Dondorp  3
Affiliations
Comment

Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?

Rob W van der Pluijm et al. Lancet Infect Dis. 2022 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The Mahidol–Oxford Research Unit (MORU) has received funding for other studies of antimalarial treatment from Fosun Pharmaceuticals, which manufactures artemisinin combination therapies. We declare no other competing interests.

Comment on

References

    1. Xu C, Wong YK, Liao FL, Jiang T, Wang J, Tu Y. Is triple artemisinin-based combination therapy necessary for uncomplicated malaria? Lancet Infect Dis. 2022;22:585–86. - PubMed
    1. Rasmussen C, Ringwald P. Is triple artemisininbased combination therapy necessary for uncomplicated malaria? Lancet Infect Dis. 2022;22:586–87. - PubMed
    1. Hamaluba M, van der Pluijm RW, Weya J, et al. Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2021;21:1395–406. - PMC - PubMed
    1. Peto TJ, Tripura R, Callery JJ, et al. Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. Lancet Infect Dis. 2022;22:867–78. - PMC - PubMed
    1. van der Pluijm RW, Amaratunga C, Dhorda M, et al. Triple artemisinin-based combination therapies for malaria—a new paradigm? Trends Parasitol. 2021;37:15–24. - PubMed